Immunovant (IMVT) vs Vaxcyte (PCVX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Immunovant (IMVT) has outperformed Vaxcyte (PCVX) over the past year, gaining 40.6% versus a gain of 15.9%. Over five years, IMVT leads with a +308.9% price change compared with +178.9% for PCVX. Vaxcyte is the larger company by market cap ($8.77 billion vs $6.57 billion), about 1.3 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | IMVT | PCVX |
|---|---|---|
| Share price | $31.77 | $55.39 |
| Market cap | $6.57B | $8.77B |
| 1-day change | -2.31% | -5.09% |
| YTD return | +24.98% | +20.05% |
| 1-year return | +40.64% | +15.93% |
| 5-year return | +308.88% | +178.90% |
| EPS (TTM) | $-2.56 | $-8.05 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Net income (latest FY) | $-505.61M | $-766.63M |
| 52-week high | $45.42 | $90.75 |
| 52-week low | $21.93 | $42.40 |
| Distance from 52-week high | -30.05% | -38.96% |
| Analyst consensus | buy | none |
| Avg. price target upside | +53.07% | +110.15% |
| Average volume | 1.42M | 2.19M |
| Shares outstanding | 206.95M | 158.30M |
| Employees | 315 | 507 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- IMVT has outperformed PCVX by 24.7 percentage points over the past year.
About Immunovant
IMVT stock →Immunovant, Inc., a clinical-stage immunology company, develops targeted therapies to meet the needs of people with autoimmune diseases. It develops IMVT-1402, a human monoclonal antibody that inhibits neonatal fragment crystallizable receptor for graves' disease, rheumatoid arthritis, sjögren's disease, cutaneous lupus erythematosus disease, myasthenia gravis, and chronic inflammatory demyelinating polyneuropathy.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 315 employees
About Vaxcyte
PCVX stock →Vaxcyte, Inc., a clinical-stage vaccine innovation company, develops conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent carrier-sparing investigational pneumococcal conjugate vaccine (PCV) for the prevention of invasive pneumococcal disease (IPD) in infants.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 507 employees
IMVT vs PCVX FAQ
Which is bigger, Immunovant or Vaxcyte?
Vaxcyte (PCVX) is larger, with a market capitalization of $8.77B compared with $6.57B for Immunovant (IMVT).
Which stock has performed better over the past year, IMVT or PCVX?
IMVT returned +40.64% over the past 12 months, compared with +15.93% for PCVX (price return, excluding dividends). Past performance does not predict future results.
Are Immunovant and Vaxcyte in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.